Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹3,797Cr
Rev Gr TTM
Revenue Growth TTM
12.97%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

ARTEMISMED
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 30.7 | 25.3 | 20.0 | 16.7 | 15.3 | 6.5 | 7.3 | 6.2 | 6.5 | 14.2 | 13.8 | 17.2 |
| 170 | 182 | 191 | 186 | 187 | 187 | 199 | 195 | 204 | 214 | 224 | 228 |
Operating Profit Operating ProfitCr |
| 13.1 | 13.3 | 15.2 | 14.9 | 16.9 | 16.2 | 17.5 | 16.1 | 15.0 | 16.2 | 18.4 | 16.4 |
Other Income Other IncomeCr | 2 | 1 | 2 | 2 | 2 | 4 | 7 | 9 | 12 | 7 | 8 | 4 |
Interest Expense Interest ExpenseCr | 5 | 7 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 7 | 7 | 7 |
Depreciation DepreciationCr | 9 | 9 | 10 | 10 | 11 | 11 | 11 | 11 | 12 | 11 | 12 | 12 |
| 14 | 13 | 19 | 16 | 20 | 22 | 31 | 27 | 29 | 30 | 39 | 30 |
| 3 | 3 | 5 | 5 | 6 | 5 | 8 | 6 | 6 | 9 | 9 | 8 |
|
Growth YoY PAT Growth YoY% | -18.9 | 17.9 | 54.4 | 12.5 | 33.5 | 69.4 | 63.4 | 78.3 | 60.3 | 28.3 | 35.6 | 7.9 |
| 5.5 | 4.7 | 6.0 | 5.3 | 6.3 | 7.4 | 9.2 | 8.9 | 9.6 | 8.3 | 10.9 | 8.2 |
| 0.8 | 0.7 | 1.0 | 0.8 | 1.0 | 1.1 | 1.4 | 1.3 | 1.5 | 1.4 | 1.9 | 1.4 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 3.4 | -27.7 | 35.9 | 32.9 | 19.1 | 6.6 | 11.2 |
| 483 | 504 | 373 | 487 | 643 | 746 | 785 | 869 |
Operating Profit Operating ProfitCr |
| 11.7 | 10.9 | 8.6 | 12.2 | 12.7 | 15.1 | 16.2 | 16.6 |
Other Income Other IncomeCr | 4 | 5 | 7 | 4 | 7 | 7 | 33 | 31 |
Interest Expense Interest ExpenseCr | 11 | 13 | 13 | 12 | 20 | 31 | 32 | 29 |
Depreciation DepreciationCr | 20 | 23 | 22 | 22 | 31 | 40 | 45 | 47 |
| 37 | 31 | 8 | 37 | 51 | 68 | 108 | 128 |
| 16 | 11 | 1 | 6 | 13 | 19 | 25 | 31 |
|
| | -4.5 | -68.3 | 409.8 | 21.1 | 29.3 | 67.2 | 17.3 |
| 3.7 | 3.4 | 1.5 | 5.7 | 5.2 | 5.6 | 8.8 | 9.3 |
| 15.5 | 1.5 | 0.5 | 2.4 | 2.9 | 3.6 | 5.4 | 6.1 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 13 | 13 | 13 | 13 | 13 | 14 | 14 | 14 |
| 280 | 300 | 307 | 346 | 390 | 435 | 824 | 869 |
Current Liabilities Current LiabilitiesCr | 177 | 158 | 118 | 138 | 206 | 185 | 216 | 247 |
Non Current Liabilities Non Current LiabilitiesCr | 84 | 115 | 160 | 210 | 291 | 332 | 298 | 290 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 113 | 118 | 109 | 127 | 170 | 180 | 539 | 521 |
Non Current Assets Non Current AssetsCr | 442 | 469 | 491 | 583 | 735 | 791 | 819 | 905 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 40 | 56 | 27 | 60 | 127 | 109 | 146 |
Investing Cash Flow Investing Cash FlowCr | -50 | -26 | -37 | -107 | -158 | -88 | -385 |
Financing Cash Flow Financing Cash FlowCr | 14 | -27 | 18 | 44 | 38 | -29 | 267 |
|
Free Cash Flow Free Cash FlowCr | -17 | 30 | -4 | -49 | -18 | 37 | 55 |
| 198.4 | 288.2 | 442.5 | 189.6 | 334.5 | 221.5 | 177.2 |
CFO To EBITDA CFO To EBITDA% | 63.4 | 91.3 | 77.5 | 88.3 | 135.3 | 82.0 | 95.9 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 183 | 294 | 608 | 913 | 2,307 | 3,781 |
Price To Earnings Price To Earnings | 0.0 | 9.2 | 45.3 | 19.1 | 23.6 | 46.9 | 45.8 |
Price To Sales Price To Sales | 0.0 | 0.3 | 0.7 | 1.1 | 1.2 | 2.6 | 4.0 |
Price To Book Price To Book | 0.0 | 0.7 | 1.2 | 2.1 | 2.7 | 6.1 | 4.9 |
| 1.2 | 4.2 | 11.6 | 11.6 | 12.2 | 19.3 | 24.2 |
Profitability Ratios Profitability Ratios |
| 99.8 | 100.4 | 99.8 | 100.0 | 100.0 | 100.0 | 100.0 |
| 11.7 | 10.9 | 8.6 | 12.2 | 12.7 | 15.1 | 16.2 |
| 3.7 | 3.4 | 1.5 | 5.7 | 5.2 | 5.6 | 8.8 |
| 12.4 | 10.7 | 4.4 | 8.8 | 10.2 | 13.0 | 12.4 |
| 7.0 | 6.2 | 1.9 | 8.7 | 9.4 | 11.0 | 9.8 |
| 3.7 | 3.3 | 1.0 | 4.4 | 4.2 | 5.1 | 6.0 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Artemis Medicare Services Ltd, launched in July 2007 by the promoters of the Apollo Tyres Group (who hold ~67% ownership), is a leading integrated healthcare provider in India. The company operates a 700+ bed quaternary care, super-specialty hospital in Gurugram (Delhi NCR), recognized as the first in the city to achieve both **Joint Commission International (JCI)** and **NABH** accreditation. Artemis has established itself as a premier destination for high-quality, globally benchmarked medical care, serving a diverse patient base—including over 100 countries for medical value travel.
---
### **Core Operations & Infrastructure**
- **Flagship Facility**: The multi-specialty hospital in Gurugram currently operates over **700 beds** across three towers, following phased commissioning of the third tower in FY25.
- **Centers of Excellence**: 14 dedicated CoEs across 40+ medical specialties, including Oncology, Cardiology, Neurology, Orthopaedics, and Gastroenterology.
- **Technology & Innovation**:
- Partnered with **KIMS, Hyderabad** to offer heart-lung transplant services.
- Launched India’s first private **Geriatrics & Longevity Department**.
- Strategic collaboration with **Abhinav Bindra Targeting Performance (ABTP)** for AI-driven, personalized physiotherapy and rehabilitation.
- Upgrading its **Hospital Information System (HIS)** and integrating **AI** for clinical decision-making, precision medicine, diagnostics, and patient engagement.
---
### **Expansion Strategy: Domestic & International**
#### **Raipur Expansion (Central India)**
- A **300+ bed super-specialty hospital** in **Raipur, Chhattisgarh**, is on track to become operational by **March 2026**.
- Key specialties include Cardiology, Oncology, Neurology, and Orthopaedics, with a built-up area of **270,000 sq ft** across two basements, ground, and six upper floors.
- **Long-term O&M and Medical Services Agreement** signed; construction is nearly complete, with interior work commencing soon.
- **Financial Impact**: Management expects significant uplift in **top line, EBITDA, and EPS within 1.5 years** of launch.
- **Revenue Outlook**: Initial **ARPOB (Average Revenue Per Occupied Bed)** is expected at ₹35,000–38,000, targeted to grow to ₹45,000 and eventually ₹60,000.
- **Competitive Edge**: Superior infrastructure and strong partnerships with renowned physicians Dr. Agarwal and Dr. Gupta to drive patient inflow.
#### **Gurugram Capacity Expansion**
- Expansion is occupancy-linked: additional beds will be added within ~one quarter once occupancy reaches **70%**.
- Plans to add **100+ beds** immediately and pursue enhanced **Floor Area Ratio (FAR)** approvals for **200 more beds** in the future.
- Addition of new towers improving **unit economics**, **economies of scale**, and **operational efficiency**.
#### **Delhi NCR Rebuild**
- Planning to reconstruct its **Delhi hospital** into a **650-bed state-of-the-art facility**.
- Execution subject to fulfillment of **conditions precedent in a binding MoU**, expected by **end-December 2025**.
- Timeline: Prioritize **Raipur breakeven**, followed by Delhi operations, then Gurugram expansion.
#### **Asset-Light Network Growth**
- **Hub-and-Spoke Model**: Smaller facilities — *Artemis Lite* and *Daffodils by Artemis* — act as referral centers for the Gurugram flagship.
- **Artemis Lite**: Neighborhood multi-specialty centers expanding in Tier 1 and 2 cities.
- **Daffodils by Artemis**: Premium maternity and child-care centers with surgical capabilities; currently 3 operational, with positive patient traction.
- New **~100-bed dedicated children’s hospital** planned in Haryana (Delhi NCR), expected in FY25 under an asset-light model.
#### **International Expansion**
- **Artemis Curepipe Hospital**, an 80-bed facility in **Mauritius**, became operational in FY24.
- First of two planned hospitals; second to follow under an O&M agreement.
- Strategic entry into **North India** via a MoU with **Dr. Vidya Sagar Kaushalya Devi Memorial Health Centre**.
- Exploring further overseas markets for scalable healthcare delivery models.
---
### **Joint Ventures & Strategic Partnerships**
- **Artemis Cardiac Care (JV with Philips Medical Systems Netherlands BV)**:
- Network of **300+ cardiac centers** planned across India.
- Currently operates **8–9 centers**, with plans to open **3–5 new centers annually**.
- Targets 25–50 centers within 3–4 years; already served **50,000+ patients**.
- Centers located in Tier 2 and Tier 3 cities, offering affordable, high-quality cardiac care.
- New unit in **Chennai** scheduled for Q1 FY24.
---
### **Financial & Operational Highlights (As of Nov 2025)**
- **Record Financial Performance**: Highest-ever **ARPOB** and strong **EBITDA margins** achieved in recent quarters, driven by improved case/payer mix and scale.
- **Bed Capacity Growth**: ~20% YoY increase in operational bed count contributing to temporary dip in occupancy %, but **absolute occupied bed numbers continue to rise**.
- **Revenue Mix**: ~30% of revenue from **international patients**, underscoring Artemis’ global reputation in **medical value travel**.
---
### **Funding & Capital Raise**
- **Jul 2025 / Aug 2024**: Raised **₹330 crores** (~$39M USD) from **International Finance Corporation (IFC)** via **compulsorily convertible debentures (CCDs)**.
- **Purpose**: Fund **quaternary and super-specialty care expansion** across Delhi NCR and Tier 2 cities (greenfield and brownfield projects).
- Capital supports both **asset-heavy** (hospitals) and **asset-light** (Lite, Daffodils, Cardiac) growth models.
---
### **Key Strengths**
- **Brand & Accreditation**: First JCI-accredited hospital in Gurugram; trusted by international patients and corporates.
- **Strategic Alliances**: Partnerships with over **100 corporates**, Philips, KIMS, IFC, and ABTP.
- **Doctor & Talent Attraction**: Strong brand equity attracts leading specialists.
- **Multi-Pronged Growth Strategy**: Combination of **flagship scaling, hub-and-spoke model, JVs, and global expansion**.
- **Financial Discipline**: Focus on unit economics, margin improvement, and capital efficiency.
---